Agency: Cordis | Branch: H2020 | Program: RIA | Phase: BIOTEC-1-2014 | Award Amount: 6.84M | Year: 2015
We aim to engineer the lifestyle of Pseudomonas putida to generate a tailored, re-factored chassis with highly attractive new-to-nature properties, thereby opening the door to the production of thus far non-accessible compounds. This industrially driven project capitalises on the outstanding metabolic endowment and stress tolerance capabilities of this versatile bacterium for the production of specialty and bulk chemicals. Specifically, we will build streamlined P. putida strains with improved ATP availability utilizing this power on demand, decoupled from growth. The well-characterized, streamlined and re-factored strain platform will offer easy-to-use plug-in opportunities for novel, DNA-encoded functions under the control of orthogonal regulatory systems. To this end, we will deploy a concerted approach of genome refactoring, model-driven circuit design, implementation of ATP control loops, structured modelling and metabolic engineering. By drawing on a starkly improved, growth-uncoupled ATP-biosynthetic machinery, empowered P. putida strains will be able to produce a) n-butanol and isobutanol and their challenging gaseous derivatives 1-butene (BE) and (iso-)butadiene (BDE) using a novel, new-to-nature route starting from glucose, as well as b) new active ingredients for crop protection, such as tabtoxin, a high-value, -lactam-based secondary metabolite with a huge potential as a new herbicide. The game-changing innovations brought in in particular the uncoupling of ATP-synthesis and production from growth - will provide strong versatility, enhanced efficiency and efficacy to the production processes, thereby overcoming current bottlenecks, matching market needs and fostering high-level research growth and development.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 396.54K | Year: 2016
Bacillus licheniformis is a preferred host for the production of industrial enzymes, including proteases for detergent and amylases and cellulases for food and biofuels. To advance its genetics/utility our key objective is to deploy SynBio tools to improve endogenous and heterologous enzyme production economics in B. licheniformis for exploitation via leading end users. Genome delivery technologies will amplify/target genes to locations validated for high-level/predictable expression, overcoming issues associated with non-targeted integration. Nuclease-based genome editing will a) address yield- compromising aspects of host metabolism under stress conditions identified through systems biology and b) capitalize on in situ protein engineering to improve endogenous enzyme function including thermotolerance and optimal activity under operating conditions. Success in these areas will reduce the cost and improve the versatility and efficiency of industrial enzymes produced in B. licheniformis.
Agency: Cordis | Branch: H2020 | Program: SME-1 | Phase: SMEInst-03-2016-2017 | Award Amount: 71.43K | Year: 2016
Ingenza will address an unmet industry need at the European level for an enabling biologics manufacturing and refinement platform targeting difficult-to-express protein structures and/or hard-to-handle potent products that requires novel, efficient, low volume manufacturing. This is a niche high-value market but the customisation and flexibility needed to address such complexity means the market is not of interest to larger established Contract Development Manufacturing Organisations. Ingenza will deliver and demonstrate a novel synthetic biology (SynBio) driven manufacturing platform that is EMA and FDA certified for GMP production of investigational and commercial biologics. This includes transitioning SynBio tools developed for industrial biotechnology towards addressing opportunities in the growing biopharmaceutical sector (CAGR 9.5%); delivering innovative biomanufacturing capabilities beyond the current state-of-the-art. To achieve this goal Ingenza will deploy its inABLE suite of proprietary SynBio tools including those for high throughput gene cloning, efficient strain screening/construction and effective bioprocess development - all integrated with state of the art single use biofermentors and downstream process technologies. Ingenzas biomanufacturing process is at TRL 6 moving towards TRL 9. The project is supported by five novel biologics developers in the EU and US, one of which will provide the case study at Phase 2 using an microbial cell factory. The Phase 1 project aims to (i) define the activities required to achieve Good Manufacturing Practice compliance for a first highly potent target biologic, (ii) demonstrate scale up, (iii) test the market to ensure a robust business model and (iv) confirm freedom to operate. Ingenza expect to reach the market in 2019 initially creating 10 high value biomanufacturing jobs. Predicted revenues should achieve an ROI of 1:9 after 6 years and 27new jobs.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Feasibility Study | Award Amount: 147.57K | Year: 2016
The proposed project is aimed towards early stage feasibility research around the biomanufacturing of commodity chemicals through the development of a novel economically attractive bioprocess that will utilise advantageous/affordable hydrocarbon feedstocks. The project will be enabled by Ingenzas unique ability to readily discover, bioengineer and exploit hydrocarbon-utilising microorganisms.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 484.60K | Year: 2015
Ribosomally Produced Peptides (RIPPs) are widely recognised as one of the most promising classes of compounds with the potential to treat many diseases including infection, cancer & inflammation. They are of great interest to the pharma industry, but are extremely costly to produce/modify - even in milligram amounts. Through the utilisation of cutting-edge techniques in combinatorial synthetic biology, this project sets out to achieve a world first; namely, to produce bespoke libraries of Modified RIPPs (M-RIPPs) in sufficient quantities to permit drug discovery screening. The project combines the fundamental knowledge of the natural processes involved in RIPP biosynthesis of the two premier UK academic groups active in the field with the applied expertise in industrial biosynthesis of a leading UK IB company. It will deliver a versatile yet robust technology platform for the production of M-RIPPs that will be commercialised via a new UK spinout company.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 200.15K | Year: 2015
Antibiotic resistant bacteria kill over 25,000 people a year in Europe and threaten a return to a time when minor infections can be fatal and routine surgery poses high risks. With development pipelines empty, there is a critical need for novel therapies to kill antibiotic resistant bacteria and serve as scaffolds for derivatisation, diversification and enhancement of efficacy, which proved successful with drugs like penicillin. This project will develop an exciting new class of antimicrobial biologics that rapidly kill bacteria, at very low doses and have great potential to prevent or treat bacterial infections including those caused by resistant bacteria. However, the development of the primary targets is hampered by their very low production in the native host and synthetic production would be prohibitively expensive. This project aims to develop efficient, adaptable and scalable microbial production systems for this novel compound class, enabling their development into a new platform of effective antibiotics.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 300.52K | Year: 2015
Synthomer and Ingenza will continue the collaboration begun in a successful TSB co-funded Feasibility Study. Synthomer have identified a market gap for a product which if made using industrial biotechnology would have improved properties and none of the drawbacks of similar materials made by existing manufacturing technologies. They anticipate that this product would be rapidly assimilated into one of their key market areas due the improved characteristics. Synthomer are a top 5 global supplier of emulsion and specialty polymer company with vast experience in this target market. Ingenza are a biotechnology enabler who develop novel bioprocesses using proprietary technologies. Ingenza will develop a bioprocess by creating a GM microorganism capable of manufacturing Synthomers product. Following the successful completion of the programme, Synthomer and Ingenza expect to enter into a lasting collaboration to optimise a sustainable manufacturing bioprocess for this unique product.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 829.34K | Year: 2015
Our pilot study (n= 23, including 15 patients on antacid medications) found this new test was 100% accurate. The results, if validated further in this proposed, thorough clinical evaluation and scientific device development programme, mean that the new test would reduce feeding incidents due to misinterpretation of pH strip and X-ray results and cut the need for chest x-rays by about a third. Wider benefits to healthcare providers and patients include 1) significant cost savings (£1 per enzymatic test versus £120 per x-ray); 2) reduced risk of misdiagnosis of misplaced NG tubes; 3) biopsychosocial improvements for patients, 4) greater confidence and reliability in nursing care and 5) improved patient care and safety. Upon validation, there would be clear potential to apply related enzymatic marker detection more broadly to detect disease, health monitoring and infection.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 315.74K | Year: 2016
This project addresses a current severe limitation in the successful industrial use of engineered microbes, namely to rapidly achieve predictable, iterative improvements in productivity to establish competitive process economics. It combines software engineering, bioinformatics, metabolomics and high-throughput construction of recombinant bacteria and yeast, to implement a system that will accelerate the development of engineered strains for next generation biosynthesis of fuel, chemicals and polymer products, manufactured from sustainable feedstocks. The project will combine the strengths of a leading UK Industrial Biotechnology SME and a state of the art university Polyomics facility to demonstrate a step change in the UK’s capability to develop new industrial bioprocesses.
Agency: GTR | Branch: Innovate UK | Program: | Phase: Collaborative Research & Development | Award Amount: 154.16K | Year: 2016
A global challenge is to improve the way in which mankind improves the consumption and disposal of commodity plastics. Alternative strategies to permit production of chemically identical “like-for-like” materials from sustainable biobased feedstocks as alternatives to existing petrochemical sources is required to help met the improve consumption and disposal of plastics. This application to Innovate UK is seeking to develop highly efficient routes to prepare polymethacrylates (i.e. Perspex) from non-fossil carbon based feedstocks. The project partners will build bespoke bacteria using state of the art synthetic biology methods to enable production of methacrylate intermediates. We shall recover and test the intermediates for their practical suitability in preparing and forming the plastics that Lucite sells to its existing customers.